Simplify's Take
What believers are saying
- June 2026 SOC 2 Type II compliance removes a major procurement blocker for pharma deals.
- June 2026 partnerships with Anthropic, Benchling, and Amazon Bio Discovery expand distribution.
- April 2026 EquiformerV3 improved energy accuracy 17% and force accuracy 8% versus prior SOTA.
What critics are saying
- Two open roles in 2026 signal a tiny team and fragile revenue base.
- Closed alpha Axon still lacks proven customer retention, conversion, and repeatable enterprise sales.
- Open-source checkpoints undercut pricing if pharma adopts EquiformerV3 without buying hosted Axon.
What makes Mirror Physics unique
- Axon unifies computational chemistry workflows with natural-language planning and execution in closed alpha.
- EquiformerV3 delivered state-of-the-art chemical physics benchmarks with MIT collaboration and open checkpoints.
- Mirror Physics sells auditable AI for scientists, emphasizing traceability, reproducibility, and enterprise compliance.
Help us improve and share your feedback! Did you find this helpful?